FMP
NASDAQ
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
9.4 USD
0.13 (1.38%)
Valuation Date:
Jul 26, 2024 4:00 PM
Share Price on Valuation Date
$9.4
Stock Beta
0.915
Shares Outstanding
9367485